Posted On: 11/15/2014 4:05:44 AM
Post# of 145213
$REGN Company News
Regeneron skids on shortfall in Eylea sales 11:15 a.m. Nov. 4, 2014 - Russ Britt
Regeneron Pharmaceuticals shares rise 8% 8:31 a.m. Oct. 17, 2014 - Sue Chang
10 rock-solid stocks for conservative investors 8:51 a.m. Sept. 17, 2014 - Philip van Doorn
S&P 500 nails the breakout point 9:35 a.m. Sept. 8, 2014 - Michael Ashbaugh
Regeneron shares run up 4.8% to lead S&P 500 gainers 8:34 a.m. Sept. 2, 2014 - Tomi Kilgore
Small health companies see large gains on a big earnings day 4:34 p.m. July 30, 2014 - Russ Britt
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 3:26 p.m. July 30, 2014 - Sue Chang
Edwards, Hospira rise as health-care companies see strong earnings 12:08 p.m. July 30, 2014 - Russ Britt
Regeneron shares jump after cholesterol drug meets test goals 10:16 a.m. July 30, 2014 - Russ Britt
Regeneron Pharmaceuticals jumps 7.7% 8:32 a.m. July 30, 2014 - Sue Chang
Dow ends at record high close but still shy of 17,000: Stock market live blog recap 3:04 p.m. July 1, 2014 - blogs.marketwatch.com
Twitter gains on new CFO; GM sales up in June 1:29 p.m. July 1, 2014 - Sue Chang
Oracle slides on disappointing results; CarMax soars 3:17 p.m. June 20, 2014 - Sue Chang
Maybe Amazon will unveil a toaster today 7:08 a.m. June 18, 2014 - Marek Fuchs
Twitter rallies ahead of earnings; 3D Systems retreats 2:49 p.m. April 29, 2014 - Sue Chang
Intuitive Surgical slumps; Facebook extends rally 2:41 p.m. April 9, 2014 - Sue Chang
44 stocks on takeover target radar: Morgan Stanley 11:48 a.m. March 25, 2014 - blogs.marketwatch.com
First Solar, H-P, Symantec are stocks to watch 3:16 p.m. March 21, 2014 - Sue Chang
First Solar extends winning streak; Symantec plunges 2:07 p.m. March 21, 2014 - Sue Chang
Nasdaq falls for 4th day in row; Dow, S&P slip for 2nd day: stock market live blog recap 2:51 p.m. March 11, 2014 - blogs.marketwatch.com
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences 9:23 a.m. Nov. 14, 2014 - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Nov. 14, 2014 - Zacks.com
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals 7:02 a.m. Nov. 13, 2014 - Investors Business Daily
3 Stocks Moving The Drugs Industry Upward 12:25 p.m. Nov. 12, 2014 - TheStreet.com
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog 11:00 a.m. Nov. 12, 2014 - Zacks.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14) 5:20 a.m. Nov. 12, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names 8:59 p.m. Nov. 11, 2014 - TheStreet.com
Stock Market News for November 11, 2014 - Market News 10:10 a.m. Nov. 11, 2014 - Zacks.com
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN) 9:51 a.m. Nov. 11, 2014 - TheStreet.com
Sanofi/Regeneron asthma drug successful in Phase 2 trial 7:44 a.m. Nov. 11, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: VZ, MRK, REGN 10:59 a.m. Nov. 10, 2014 - TheStreet.com
Regeneron updates guidance after Q3 results 11:09 a.m. Nov. 6, 2014 - Seeking Alpha
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis 8:32 a.m. Nov. 6, 2014 - Seeking Alpha
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way 11:24 a.m. Nov. 5, 2014 - TheStreet.com
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog 9:46 a.m. Nov. 5, 2014 - Zacks.com
Jazz Beats And Raises Views; Regeneron Misses In Q3 6:02 p.m. Nov. 4, 2014 - Investors Business Daily
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog 4:30 p.m. Nov. 4, 2014 - Zacks.com
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript 4:16 p.m. Nov. 4, 2014 - TheStreet.com
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter 9:51 a.m. Nov. 4, 2014 - Investors Business Daily
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma 1:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Regeneron Reports Third Quarter 2014 Financial and Operating Results 6:30 a.m. Nov. 4, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 4:01 p.m. Nov. 3, 2014 - PR Newswire - PRF
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter 9:15 a.m. Nov. 3, 2014 - PR Newswire - PRF
New Solution for Patients, Quarterly Financial Results, Clinical Study Initiation, Merger Updates, and Product Launch - Research Reports on CVS, Valeant, Regeneron, Allergan and Agilent 9:20 a.m. Oct. 23, 2014 - PR Newswire - PRF
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma 9:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study 7:00 a.m. Oct. 17, 2014 - PR Newswire - PRF
Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year 2:00 p.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments 8:30 a.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014 4:01 p.m. Oct. 15, 2014 - PR Newswire - PRF
Critical Alerts For ITT Education, EOG Resources, Mobileye NV, CBS and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Dividend, Regulatory Warning, Board Statements, and Technical Updates - Research Reports on Regeneron, CVS Health, Valeant, Allergan and Jazz 9:15 a.m. Oct. 7, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) 4:58 p.m. Oct. 6, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 1:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Regulatory Approvals, Senior Notes Redemption, and Technical Updates - Research Reports on Tekmira, Regeneron, Valeant, Teva and United Therapeutics 9:20 a.m. Sept. 25, 2014 - PR Newswire - PRF
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan 2:30 a.m. Sept. 22, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema 7:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences, Regeneron Pharma, Sunesis Pharma, and Idera Pharma 9:10 a.m. Sept. 9, 2014 - PR Newswire - PRF
Critical Alerts For Rocket Fuel, General Motors, International Business Machines, Google and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Sept. 8, 2014 - PR Newswire - PRF
Regeneron skids on shortfall in Eylea sales 11:15 a.m. Nov. 4, 2014 - Russ Britt
Regeneron Pharmaceuticals shares rise 8% 8:31 a.m. Oct. 17, 2014 - Sue Chang
10 rock-solid stocks for conservative investors 8:51 a.m. Sept. 17, 2014 - Philip van Doorn
S&P 500 nails the breakout point 9:35 a.m. Sept. 8, 2014 - Michael Ashbaugh
Regeneron shares run up 4.8% to lead S&P 500 gainers 8:34 a.m. Sept. 2, 2014 - Tomi Kilgore
Small health companies see large gains on a big earnings day 4:34 p.m. July 30, 2014 - Russ Britt
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 3:26 p.m. July 30, 2014 - Sue Chang
Edwards, Hospira rise as health-care companies see strong earnings 12:08 p.m. July 30, 2014 - Russ Britt
Regeneron shares jump after cholesterol drug meets test goals 10:16 a.m. July 30, 2014 - Russ Britt
Regeneron Pharmaceuticals jumps 7.7% 8:32 a.m. July 30, 2014 - Sue Chang
Dow ends at record high close but still shy of 17,000: Stock market live blog recap 3:04 p.m. July 1, 2014 - blogs.marketwatch.com
Twitter gains on new CFO; GM sales up in June 1:29 p.m. July 1, 2014 - Sue Chang
Oracle slides on disappointing results; CarMax soars 3:17 p.m. June 20, 2014 - Sue Chang
Maybe Amazon will unveil a toaster today 7:08 a.m. June 18, 2014 - Marek Fuchs
Twitter rallies ahead of earnings; 3D Systems retreats 2:49 p.m. April 29, 2014 - Sue Chang
Intuitive Surgical slumps; Facebook extends rally 2:41 p.m. April 9, 2014 - Sue Chang
44 stocks on takeover target radar: Morgan Stanley 11:48 a.m. March 25, 2014 - blogs.marketwatch.com
First Solar, H-P, Symantec are stocks to watch 3:16 p.m. March 21, 2014 - Sue Chang
First Solar extends winning streak; Symantec plunges 2:07 p.m. March 21, 2014 - Sue Chang
Nasdaq falls for 4th day in row; Dow, S&P slip for 2nd day: stock market live blog recap 2:51 p.m. March 11, 2014 - blogs.marketwatch.com
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences 9:23 a.m. Nov. 14, 2014 - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Nov. 14, 2014 - Zacks.com
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals 7:02 a.m. Nov. 13, 2014 - Investors Business Daily
3 Stocks Moving The Drugs Industry Upward 12:25 p.m. Nov. 12, 2014 - TheStreet.com
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog 11:00 a.m. Nov. 12, 2014 - Zacks.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14) 5:20 a.m. Nov. 12, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names 8:59 p.m. Nov. 11, 2014 - TheStreet.com
Stock Market News for November 11, 2014 - Market News 10:10 a.m. Nov. 11, 2014 - Zacks.com
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN) 9:51 a.m. Nov. 11, 2014 - TheStreet.com
Sanofi/Regeneron asthma drug successful in Phase 2 trial 7:44 a.m. Nov. 11, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: VZ, MRK, REGN 10:59 a.m. Nov. 10, 2014 - TheStreet.com
Regeneron updates guidance after Q3 results 11:09 a.m. Nov. 6, 2014 - Seeking Alpha
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis 8:32 a.m. Nov. 6, 2014 - Seeking Alpha
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way 11:24 a.m. Nov. 5, 2014 - TheStreet.com
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog 9:46 a.m. Nov. 5, 2014 - Zacks.com
Jazz Beats And Raises Views; Regeneron Misses In Q3 6:02 p.m. Nov. 4, 2014 - Investors Business Daily
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog 4:30 p.m. Nov. 4, 2014 - Zacks.com
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript 4:16 p.m. Nov. 4, 2014 - TheStreet.com
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter 9:51 a.m. Nov. 4, 2014 - Investors Business Daily
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma 1:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Regeneron Reports Third Quarter 2014 Financial and Operating Results 6:30 a.m. Nov. 4, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 4:01 p.m. Nov. 3, 2014 - PR Newswire - PRF
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter 9:15 a.m. Nov. 3, 2014 - PR Newswire - PRF
New Solution for Patients, Quarterly Financial Results, Clinical Study Initiation, Merger Updates, and Product Launch - Research Reports on CVS, Valeant, Regeneron, Allergan and Agilent 9:20 a.m. Oct. 23, 2014 - PR Newswire - PRF
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma 9:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study 7:00 a.m. Oct. 17, 2014 - PR Newswire - PRF
Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year 2:00 p.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments 8:30 a.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014 4:01 p.m. Oct. 15, 2014 - PR Newswire - PRF
Critical Alerts For ITT Education, EOG Resources, Mobileye NV, CBS and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Dividend, Regulatory Warning, Board Statements, and Technical Updates - Research Reports on Regeneron, CVS Health, Valeant, Allergan and Jazz 9:15 a.m. Oct. 7, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) 4:58 p.m. Oct. 6, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 1:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Regulatory Approvals, Senior Notes Redemption, and Technical Updates - Research Reports on Tekmira, Regeneron, Valeant, Teva and United Therapeutics 9:20 a.m. Sept. 25, 2014 - PR Newswire - PRF
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan 2:30 a.m. Sept. 22, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema 7:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences, Regeneron Pharma, Sunesis Pharma, and Idera Pharma 9:10 a.m. Sept. 9, 2014 - PR Newswire - PRF
Critical Alerts For Rocket Fuel, General Motors, International Business Machines, Google and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Sept. 8, 2014 - PR Newswire - PRF
(0)
(0)
